Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group

NS Raje, E Anaissie, SK Kumar, S Lonial… - The Lancet …, 2022 - thelancet.com
Infection remains the leading cause of morbidity and mortality in patients with multiple
myeloma because of the cumulative effect of disease, treatment, and host-related factors …

Cancer-associated venous thromboembolism: burden, mechanisms, and management

C Ay, I Pabinger, AT Cohen - Thrombosis and haemostasis, 2017 - thieme-connect.com
Venous thromboembolism (VTE) is a significant health problem in the general population
but especially in cancer patients. In this review, we discuss the epidemiology and burden of …

[HTML][HTML] Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

P Moreau, J San Miguel, P Sonneveld, MV Mateos… - Annals of oncology, 2017 - Elsevier
Multiple myeloma (MM) accounts for 1% of all cancers and∼ 10% of all haematological
malignancies. The incidence in Europe is 4.5–6.0/100 000/year with a median age at …

[PDF][PDF] Advances in Understanding and Managing Multiple Myeloma: A Comprehensive Review

I Karunarathna, K Gunawardana, P Aluthge… - 2024 - researchgate.net
Multiple myeloma (MM) is a clonal plasma cell disorder marked by the production of
monoclonal immunoglobulins, leading to various end-organ damages including …

IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies

G Lancman, K Parsa, K Kotlarz, L Avery… - Blood Cancer …, 2023 - aacrjournals.org
BCMA-targeted bispecific antibodies (BiAb) are efficacious in relapsed/refractory multiple
myeloma; however, serious infections have emerged as important toxicities. In this …

[PDF][PDF] Understanding multiple myeloma: Diagnosis, clinical presentation, and management

I Karunarathna, K Gunawardana, P Aluthge, K De Alvis - 2024 - researchgate.net
Multiple myeloma (MM) is a clonal plasma cell disorder marked by the production of
monoclonal immunoglobulins, leading to various end-organ damages including …

[PDF][PDF] Understanding multiple myeloma: Key challenges and emerging treatments

I Karunarathna, K Gunawardana, P Aluthge, K De Alvis - 2024 - researchgate.net
Multiple myeloma (MM) is a clonal plasma cell disorder marked by the production of
monoclonal immunoglobulins, leading to various end-organ damages including …

Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International …

M Cavo, E Terpos, C Nanni, P Moreau… - The lancet …, 2017 - thelancet.com
Summary The International Myeloma Working Group consensus aimed to provide
recommendations for the optimal use of 18 fluorodeoxyglucose (18 F-FDG) PET/CT in …

Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and …

P Moreau, M Attal, D Caillot, M Macro… - Journal of clinical …, 2017 - ascopubs.org
Purpose Magnetic resonance imaging (MRI) and positron emission tomography–computed
tomography (PET-CT) are important imaging techniques in multiple myeloma (MM). We …

The diagnosis and treatment of multiple myeloma

C Gerecke, S Fuhrmann, S Strifler… - Deutsches …, 2016 - pmc.ncbi.nlm.nih.gov
Background Multiple myeloma is a malignant disease of plasma cells with a worldwide
incidence of 6–7 cases per 100 000 persons per year. It is among the 20 most common …